QTTB Stock Summary and Trading Ideas (Q32 Bio | NASDAQ:QTTB)

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Q32 Bio trades on the NASDAQ stock market under the symbol QTTB.

As of May 9, 2024, QTTB stock price climbed to $26.80 with 20,306 million shares trading.

QTTB has a market cap of $319.71 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that QTTB belongs to (by Net Assets): VTI, VXF, FESM, AVSC.

QTTB support price is $24.42 and resistance is $28.15 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that QTTB stock will trade within this expected range on the day.